efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight[Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open- label Phase 3b clinical trial...]### Lilly to participate in TD Cowen's 46th Annual Health Care Conference[Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice...][More Releases From This Source]## Explore[He ...

Everyone has been talking about Ozempic in recent years. You may have seen the name in the news or even know someone who is taking this blockbuster drug. Though Ozempic, made by Novo Nordisk, is approved for type 2 diabetes, the drug has also been prescribed for weight loss. It's part of the popular GLP-1 class of drugs. Novo was first to market with a GLP-1 drug in 2017 and maintained leadership for a while. But that has changed over the past year, as another player roared into the top spot. So, as an i ...

2026.02．19 当地时间2月18日，礼来公司公布了一项最新研究结果，显示出该公司的减重药替尔泊肽在肥胖合并自 身免疫性疾病方面的潜力。 一项针对274名银屑病患者的后期研究数据显示，使用替尔泊肽与该公司现有生物制剂依奇珠单抗联合 治疗的效果优于单独使用依奇珠单抗的疗效，并且联合治疗可同时实现减轻皮肤症状及体重减轻的双重 效果。 与此同时，随着礼来的口服减重药即将获批，双方在口服减重制剂领域的竞争已经开打。根据一份上周 公布的备案文件，礼来正在为口服减重药大举备货，公司预上市库存规模已达15亿美元，较去年同期的 5.5亿美元大幅增长。 微信编辑 | 雨林 责任编辑：王珂 2026.02．19 数据显示，在治疗36周时，约27.1%接受联合疗法的患者达到了银屑病完全清除的治疗目标，同时实现 10%的体重减轻；而单独使用依奇珠单抗的患者达到治疗目标的比例仅5.8%。 银屑病是一种慢性自身免疫性疾病，会导致皮肤上出现瘙痒、鳞屑斑块。这项研究结果显示了此类减重 药在治疗肥胖合并症方面的潜力，大部分肥胖患者还伴有至少一种与体重相关的合并症。 目前，礼来及主要竞争对手诺和诺德正在多个市场针对多种减重疗法新适应症方面展 ...

目前，礼来及主要竞争对手诺和诺德正在多个市场针对多种减重疗法新适应症方面展开激烈竞逐。 与此同时，随着礼来的口服减重药即将获批，双方在口服减重制剂领域的竞争已经开打。根据一份上周 公布的备案文件，礼来正在为口服减重药大举备货，公司预上市库存规模已达15亿美元，较去年同期的 5.5亿美元大幅增长。 银屑病是一种慢性自身免疫性疾病，会导致皮肤上出现瘙痒、鳞屑斑块。这项研究结果显示了此类减重 药在治疗肥胖合并症方面的潜力，大部分肥胖患者还伴有至少一种与体重相关的合并症。 目前，礼来及主要竞争对手诺和诺德正在多个市场针对多种减重疗法新适应症方面展开激烈竞逐。 新适应症的开拓意味着患者范围的扩大。就在上周，替尔泊肽获得中国国家药品监督管理局批准，新增 用于成人2型糖尿病（T2DM）单药治疗。此前，替尔泊肽用于接受二甲双胍和（或）磺脲类药物治疗 血糖仍控制不佳的成人2型糖尿病患者。 在欧洲市场，诺和诺德减重药物司美格鲁肽7.2mg更高剂量疗法也于本周获得批准，为医生和患者提供 了更多治疗选择。 当地时间2月18日，礼来公司公布了一项最新研究结果，显示出该公司的减重药替尔泊肽在肥胖合并自 身免疫性疾病方面的潜力。 一项针对 ...

本文源自：金融界AI电报 贝伦贝格：将礼来(LLY.N)目标价从950美元上调至1050美元。 ...

Impax Asset Management's "Impax US Sustainable Economy Fund" released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark on the back of sustainability tilts and stock-specific gains, particularly within Health Care and Financials. On an annual basi ...

Key Takeaways Lilly has filed orforglipron for obesity and is advancing retatrutide in late-stage studiesOrforglipron filings span the U.S. and EU, with a U.S. obesity launch expected in Q2 2026.Retatrutide showed strong weight loss and pain relief in patients with obesity and knee osteoarthritis painEli Lilly and Company (LLY) is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, supported by the strong success of its GLP-1–based therapies — Mounjaro for type II di ...

Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting it certain rights to develop and commercialise clazakizumab, an antibody aimed a... ...

Investing in pharmaceutical stocks can be tricky. Drugmakers put an enormous amount of time and money into research and development of new products. It takes more than 10 years to develop a new drug and costs, on average, $2.6 billion. Yet the vast majority of new drugs never make it to market. The success rate of new drug development, from conception to FDA approval, is about 8%. And while a drug patent is typically 20 years, much of that time is eaten up during the development period, before a drug goes ...

格隆汇2月17日｜礼来计划将印度打造成为其全球供应链的中心，作为公司先前承诺在印度投资10亿美 元用于合约生产的一部分。公司旗下重磅减肥药Mounjaro在南亚国家上市几个月后销量倍翻，而其目前 在印度并没有自家生产设施，计划利用印度强大的合约生产体系，将其在印度生产的药品出口到世界各 地的市场，作为其更广泛的供应网络的一部分。公司还计划将更多产品引入印度。 ...